checkAd

    DGAP-News  217  0 Kommentare PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA - Seite 4


    Vice President Investor Relations/Public Relations
    PAION AG
    Martinstrasse 10-12
    52062 Aachen - Germany
    Phone +49 241 4453-152
    E-mail r.penner@paion.com
    www.paion.com

    1. Salmasi, V., et al., Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney and Myocardial Injury after Noncardiac Surgery: A Retrospective Cohort Analysis. Anesthesiology, 2017. 126(1): p. 47-65.

    2. Sessler, D.I., et al., Perioperative Quality Initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth, 2019. 122(5): p. 563-574.



    Disclaimer:
    This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.



    Lesen Sie auch

    19.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de


    Language: English
    Company: PAION AG
    Martinstr. 10-12
    52062 Aachen
    Germany
    Phone: +49 (0)241-4453-0
    Fax: +49 (0)241-4453-100
    E-mail: info@paion.com
    Internet: www.paion.com
    ISIN: DE000A0B65S3
    WKN: A0B65S
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
    EQS News ID: 1149513
    Seite 4 von 5


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA - Seite 4 DGAP-News: PAION AG / Key word(s): Research Update PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA 19.11.2020 / 22:48 The issuer is solely responsible for the content of this announcement. PAION REPORTS …